ModiusHealth

What ModiusHealth does

Neurovalens, operating commercially as ModiusHealth, is a Northern Ireland-headquartered medical device company that develops non-invasive neurostimulation headsets for chronic health conditions. Its portfolio comprises three FDA-cleared/approved prescription devices: Modius Sleep (an FDA-cleared headset that targets the vestibular system to treat insomnia), Modius Spero (the world's first FDA De Novo authorized neuromodulation device to treat symptoms associated with PTSD), and Modius Lean (an FDA-approved weight management device developed in collaboration with the Stanford Neurosurgery Team). The underlying technology is electrical neurostimulation of the vestibular nerve, designed by neurologists as a drug-free alternative to pharmacotherapy for treatment-resistant indications.

The company generates revenue through two streams: hardware sales of prescription medical devices and recurring sales of stimulation pads and accessories via its direct e-commerce store. In the United States, distribution is concentrated through an exclusive partnership with the Veterans Affairs (VA) healthcare system, where Modius Sleep is physician-prescribed to eligible veterans. Following EU MDR certification in 2026, the company has begun direct commercial expansion into European and UK markets, and is pursuing Middle East entry via the WHX Dubai 2026 event with the Association of British HealthTech Industries (ABHI). Pricing is not publicly disclosed; the VA relationship operates on a quote-based, multi-year contract structure, while accessories are sold direct-to-consumer.

Neurovalens is privately held, employs 11–50 people, and is led by CEO Jason McKeown alongside Chief Commercial & Marketing Officer Tony Wilcox and Chief Scientific Officer Paul McGeoch. The company has raised approximately £6m in 2025 (led by the Investment Fund for Northern Ireland) on top of earlier rounds in 2014 and 2017, and holds FDA, EU MDR, 21 CFR Part 11, and GDPR compliance credentials. Named customers are limited to the VA, and the company is actively featured in major business and health media outlets including TechCrunch, Forbes, BBC, MassDevice, and Fox Business.

Name

ModiusHealth

Legal name

Neurovalens

Website

https://modiushealth.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Neurovalens (operating as ModiusHealth) is a Northern Ireland-based medical device company developing FDA-cleared, non-invasive neurostimulation headsets to treat insomnia, PTSD, and obesity. Products are distributed through the U.S. VA healthcare system for veterans and via e-commerce for accessories.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL)

akta.pro secondary industry

Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)

Keywords

• Neuromodulation devices
• Neurostimulation technology
• Medical device manufacturing
• Sleep disorder treatment
• PTSD treatment devices

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Hardware Sales: Sale of neurostimulation hardware devices (Modius Sleep, Modius Spero, Modius Lean) through prescription and direct channels. Devices are FDA-cleared/authorized medical devices sold to healthcare providers and patients.
2. Accessories and Consumables: Recurring revenue from stimulation pads and accessories sold through the company's e-commerce store for device maintenance and continued use.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

ModiusHealth (Neurovalens) develops, manufactures, and sells FDA-cleared non-invasive neurostimulation medical devices that treat chronic health conditions including insomnia (Modius Sleep), PTSD symptoms (Modius Spero), and weight management (Modius Lean). Devices are physician-prescribed and distributed primarily through the U.S. Veterans Affairs healthcare system, with expansion into EU/UK markets, alongside recurring sales of stimulation pads and accessories through an e-commerce store.

Product overview

Neurovalens (operating as ModiusHealth) is a global health-tech company that creates non-invasive neurostimulation products to address chronic health conditions. The product portfolio consists of three FDA-cleared/approved medical devices: Modius Sleep (insomnia treatment), Modius Spero (PTSD treatment - world's first FDA-authorized neuromodulation device for PTSD), and Modius Lean (weight management). All devices are drug-free, non-invasive neurostimulation headsets designed by neurologists. Products are available primarily through the VA for Veterans, with EU/UK approvals for Modius Sleep.

Differentiator

Problem solved

Functional benefit

Brands

• Modius Sleep: FDA-cleared prescribed treatment for insomnia, exclusively available to Veterans through the VA. Non-invasive neurostimulation headset.
• Modius Spero
• Modius Lean

Products and services

• Modius Sleep FDA-cleared, physician-prescribed non-invasive neurostimulation headset for the treatment of insomnia, targeting the vestibular system. Available exclusively to U.S. Veterans through the VA healthcare system, and approved for sale in Europe and the UK under EU MDR certification.
• Modius Spero FDA De Novo approved non-invasive neuromodulation device — the world's first FDA-authorized neuromodulation device to treat symptoms associated with PTSD, a condition affecting an estimated 13 million Americans annually.
• Modius Lean FDA-approved non-invasive neurostimulation device for weight management, developed in collaboration with the Stanford Neurosurgery Team, targeting metabolic and weight outcomes through vestibular neurostimulation.
• Stimulation Pads and Accessories Stimulation pads and replacement accessories for Modius neurostimulation headsets, sold direct-to-consumer through the company's online store to support continued device maintenance and use.

Quantifiable outcome

• FDA-cleared for insomnia treatment
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Association of British HealthTech Industries (ABHI)minorGTM or Marketing Partner · 1 January 2026Partnership for exhibition and presence at WHX Dubai 2026, the Middle East's flagship healthcare and life sciences event, facilitating market expansion into the Middle East region.
• Stanford Neurosurgery TeamcoreStrategic or Co-development Partner · 1 January 2026Collaborative development partnership with Stanford Neurosurgery Team leading to FDA approval for Modius Lean weight management neurostimulation device.
• Veterans Affairs (VA) Healthcare SystemcoreChannel Partner/ Reseller/ DistributorExclusive distribution partnership making Modius Sleep and other Modius devices available to veterans through VA healthcare facilities. Modius devices are FDA-cleared and physician-prescribed for eligible veterans.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Fisher Wallace: Fisher Wallace manufactures wearable non-invasive neurostimulation devices FDA-cleared for insomnia, depression, and anxiety. Closest direct competitor given overlapping product form factor (headset/wearable), identical non-invasive neurostimulation modality, and shared insomnia and CNS indication targets.
• ElectroCore: ElectroCore (now NeurAxis) develops non-invasive vagus nerve stimulation (nVNS) devices FDA-cleared for migraine, cluster headache, and other conditions. Highly comparable as a non-invasive neurostimulation medical device company pursuing multiple FDA-cleared indications in CNS.
• NeuroPace: NeuroPace markets the RNS System, an FDA-approved implantable closed-loop neurostimulator for refractory epilepsy. Comparable as a neurostimulation medical device company with FDA approvals in CNS, though NeuroPace's approach is implantable rather than non-invasive.
• eNeura: eNeura manufactures the FDA-cleared single-pulse transcranial magnetic stimulation (sTMS) device for migraine. Directly comparable as a non-invasive neurostimulation headset medical device addressing chronic neurological conditions via physician prescription.
• Inspire Medical Systems: Inspire Medical Systems manufactures implantable neurostimulation devices for obstructive sleep apnea, FDA-approved and reimbursed by Medicare. Comparable as a neurostimulation company addressing sleep-related indications via physician-prescribed medical devices with a similar regulatory and commercialization model.
• Cefaly: Cefaly makes FDA-cleared external trigeminal nerve stimulation devices for migraine prevention and treatment. Directly comparable as a non-invasive, prescription neurostimulation headset addressing chronic neurological conditions with similar regulatory pathway and reimbursement model.
• Soterix Medical: Soterix Medical develops clinical-grade non-invasive brain stimulation and neurotechnology platforms used in research and therapeutic applications. Comparable as a neurostimulation medical technology company targeting CNS indications with FDA-cleared hardware.
• Alpha-Stim: Alpha-Stim produces FDA-cleared cranial electrotherapy stimulation devices for anxiety, insomnia, depression, and pain. Highly comparable in delivery mechanism (non-invasive electrical neurostimulation), clinical positioning, and prescription-based distribution model.

Emerging players

• Big Health (Sleepio): Big Health's Sleepio is a digital therapeutic for insomnia that has received FDA clearance as a prescription treatment for chronic insomnia. Competes for the same physician-prescribed insomnia treatment market as Modius Sleep, representing an alternative non-pharmacological modality.
• Pear Therapeutics: Pear Therapeutics pioneered FDA-authorized prescription digital therapeutics (PDTs) for insomnia and other CNS conditions. Comparable as a non-pharmacological, FDA-authorized treatment modality competing for the same physician-prescribed insomnia market, though delivered via software rather than hardware.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ModiusHealth
• Facebookfacebook.com/Neurovalens
• LinkedInlinkedin.com/company/neurovalens
• Instagraminstagram.com/neurovalens

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ModiusHealth